This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD Life Sciences to Aid Becton, Dickinson (BDX) Q1 Earnings
by Zacks Equity Research
BD's (BDX) core Life Sciences arm is expected to have driven first-quarter performance.
Why Is Glaukos (GKOS) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Q3 Loss Narrower Than Expected, '19 View Up
by Zacks Equity Research
Glaukos' (GKOS) Q3 revenues surge year over year. Also, the company raises 2019 revenue guidance.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 41.18% and 3.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Glaukos (GKOS) Up 2.3% Since Last Earnings Report?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised
by Zacks Equity Research
Glaukos (GKOS) raises 2019 revenues view; optimistic about Avedro buyout.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -10.00% and 4.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Down 2.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 66.67% and 7.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Banks on Solid Pipeline Amid Stiff Competition
by Zacks Equity Research
Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.
Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -35.71% and 8.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Jumps: Stock Rises 7.2%
by Zacks Equity Research
Glaukos (GKOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -15.38% and 5.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Weakness Seen in Glaukos (GKOS) Estimates: Should You Stay Away?
by Zacks Equity Research
Glaukos (GKOS) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Cerner (CERN) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Cerner Corp (CERN) reported adjusted first-quarter 2017 earnings of 56 cents per share, beating the Zacks Consensus Estimate of 53 cents.
CONMED (CNMD) Q1 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
CONMED Corporation (CNMD) reported first-quarter 2017 adjusted earnings of 38 cents per share, beating the Zacks Consensus Estimate by 4 cents.
Stryker (SYK) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Stryker Corp (SYK) reported adjusted earnings of $1.48 per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate by 5 cents.
DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues
by Zacks Equity Research
DexCom Inc. (DXCM) reported loss of nine cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 10 cents.
The Cooper Companies (COO) Beats Earnings Estimates in Q1
by Zacks Equity Research
The Cooper Companies Inc.(COO) reported adjusted earnings of $1.93 in first-quarter fiscal 2017, surpassing the Zacks Consensus Estimate by 7 cents and improving 5.5% on a year-over-year basis.
NxStage Medical: NxGen Hemodialysis System Now CE Marked
by Zacks Equity Research
NxStage Medical, Inc. (NXTM) recently announced the receipt of CE mark for its NxGen Hemodialysis System, an innovative device with easier user interface and integrated blood pressure monitor system for patients performing home hemodialysis.